FBRXForte Biosciences, Inc.

Nasdaq fortebiorx.com


$ 0.72 $ 0.00 (0 %)    

Tuesday, 07-May-2024 08:40:44 EDT
QQQ $ 440.27 $ 0.75 (0.17 %)
DIA $ 388.40 $ 1.68 (0.43 %)
SPY $ 516.34 $ 5.28 (1.03 %)
TLT $ 90.16 $ 0.35 (0.39 %)
GLD $ 215.21 $ 2.24 (1.05 %)
$ 0.72
$ 0.72
$ 0.00 x 0
$ 0.00 x 0
$ 0.72 - $ 0.72
$ 0.38 - $ 1.11
11,500
na
26.2M
$ 1.75
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-18-2024 12-31-2023 10-K
2 11-13-2023 09-30-2023 10-Q
3 08-14-2023 06-30-2023 10-Q
4 05-15-2023 03-31-2023 10-Q
5 03-31-2023 12-31-2022 10-K
6 11-14-2022 09-30-2022 10-Q
7 08-15-2022 06-30-2022 10-Q
8 05-16-2022 03-31-2022 10-Q
9 03-31-2022 12-31-2021 10-K
10 11-08-2021 09-30-2021 10-Q
11 08-16-2021 06-30-2021 10-Q
12 05-10-2021 03-31-2021 10-Q
13 03-16-2021 12-31-2020 10-K
14 11-09-2020 09-30-2020 10-Q
15 08-10-2020 06-30-2020 10-Q
16 04-23-2020 03-31-2020 10-Q
17 02-27-2020 12-31-2019 10-K
18 11-12-2019 09-30-2019 10-Q
19 08-08-2019 06-30-2019 10-Q
20 05-07-2019 03-31-2019 10-Q
21 02-27-2019 12-31-2018 10-K
22 11-08-2018 09-30-2018 10-Q
23 08-09-2018 06-30-2018 10-Q
24 05-11-2018 03-31-2018 10-Q
25 03-09-2018 12-31-2017 10-K
26 11-08-2017 09-30-2017 10-Q
27 08-09-2017 06-30-2017 10-Q
28 05-23-2017 03-31-2017 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 ladenburg-thalmann-upgrades-forte-biosciences-to-buy-announces-275-price-target

Ladenburg Thalmann analyst Michael Higgins upgrades Forte Biosciences (NASDAQ:FBRX) from Neutral to Buy and announces $2.75 ...

 forte-biosciences-inc-announces-2023-eps-100-vs-080-yoy

2023 Operating ResultsResearch and development expenses were $21.9 million for the year ended December 31, 2023, compared to $5...

 funicular-funds-in-amended-13d-filing-said--on-oct-28-2023-forte-biosciences-filed-vexatious-legal-action-against-jacob-ma-weaver-and-funicular-funds-believe-allegations-in-the-complaint-are-baseless-and-without-merit

 Funicular Funds has a 5.59% stake in Forte Biosciences

 research-frontiers-and-3-other-stocks-under-1-insiders-are-buying

The Dow Jones index closed higher by over 150 points on Tuesday. When insiders purchase or sell shares, it indicates their conf...

 riskon-international-and-3-other-stocks-under-2-insiders-are-buying

The Dow Jones closed higher by over 100 points on Friday. When insiders purchase or sell shares, it indicates their confidence ...

 insiders-buying-vintage-wine-estates-and-3-other-stocks-under-1

The Dow Jones closed higher by over 180 points on Wednesday. When insiders purchase or sell shares, it indicates their confiden...

 forte-biosciences-q3-eps-026-down-from-018-yoy

Forte Biosciences (NASDAQ:FBRX) reported quarterly losses of $(0.26) per share. This is a 44.44 percent decrease over losses of...

 stocks-that-hit-52-week-lows-on-tuesday

  On Tuesday, 647 companies set new 52-week lows.

 stocks-that-hit-52-week-lows-on-tuesday

  On Tuesday, 386 stocks made new 52-week lows.

 forte-biosciences-q2-eps-042-down-from-021-yoy

Forte Biosciences (NASDAQ:FBRX) reported quarterly losses of $(0.42) per share. This is a 100 percent decrease over losses of $...

 stocks-that-hit-52-week-lows-on-friday

  On Friday, 73 companies reached new 52-week lows.

 earnings-scheduled-for-may-26-2023

Companies Reporting Before The Bell • LightInTheBox Holding (NYSE:LITB) is estimated to report earnings for its first quarter.

 forte-biosciences-q1-eps-032-down-from-017-yoy

Forte Biosciences (NASDAQ:FBRX) reported quarterly losses of $(0.32) per share. This is a 88.24 percent decrease over losses of...

 forte-biosciences-inc-announces-fy22-results-and-provides-business-update-fy22-eps-080-vs-155-yoy

Full Year 2022 Business Highlights In January, Forte appointed Mr. David Gryska to the Board of Directors. Mr. Gryska was prev...

 forte-biosciences-inc---common-stock-q3-eps-018-up-from-054-yoy

Forte Biosciences, Inc. - Common Stock (NASDAQ:FBRX) reported quarterly losses of $(0.18) per share. This is a 66.67 percent in...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION